MASTER AGREEMENT BY AND AMONG MSP TECHNOLOGY (U.S.) COMPANY LLC, MSP SINGAPORE COMPANY, LLC, SCHERING CORPORATION, SCHERING-PLOUGH CORPORATION, AND MERCK & CO., INC. DATED AS OF DECEMBER 18, 2001Master Agreement • July 31st, 2008 • Merck & Co Inc • Pharmaceutical preparations • Delaware
This Master Agreement is dated as of December 18, 2001 (the “Effective Date”), by and among MSP Technology (U.S.) Company LLC (“MSP Technology”), MSP Singapore Company, LLC (the “Singapore Partnership”), Schering Corporation, Schering-Plough Corporation
CHOLESTEROL GOVERNANCE AGREEMENT BY AND AMONG MSP DISTRIBUTION SERVICES (C) LLC, MSP MARKETING SERVICES (C) LLC, MSP TECHNOLOGY (US) COMPANY LLC, MERCK CARDIOVASCULAR HEALTH COMPANY, MERCK TECHNOLOGY (US) COMPANY, INC., SCHERING MSP CORPORATION,...Cholesterol Governance Agreement • July 31st, 2008 • Merck & Co Inc • Pharmaceutical preparations • Delaware
This Cholesterol Governance Agreement is dated as of May 22, 2000, by and among MSP DISTRIBUTION SERVICES (C) LLC (“Distribution LLC”), MSP MARKETING SERVICES (C) LLC (“Marketing LLC”), MSP TECHNOLOGY (US) COMPANY LLC (“Technology LLC”), MERCK CARDIOVASCULAR HEALTH COMPANY (“M-Cardio Sub”), MERCK TECHNOLOGY (US) COMPANY, INC., SCHERING MSP CORPORATION (“S-MSP Corp.”), SCHERING SALES MANAGEMENT, INC. (“S-Sales Sub”), SCHERING SALES CORPORATION, SCHERING MSP PHARMACEUTICALS L.P., MSP CHOLESTEROL LLC (“Cholesterol LLC”), MSP SINGAPORE COMPANY, LLC (the “Singapore Partnership”), MSD TECHNOLOGY SINGAPORE Pte. Ltd., MSD VENTURES SINGAPORE Pte. Ltd., OSAMMOR Pte. Ltd. (to be renamed SCHERING-PLOUGH (SINGAPORE) Pte. Ltd.), CITIMERE Pte. Ltd. (to be renamed SCHERING-PLOUGH (SINGAPORE) RESEARCH Pte. Ltd.), Schering Corporation, Schering-Plough Corporation, a New Jersey corporation (“S-P”), and Merck & Co., Inc., a New Jersey corporation (“M”).
Confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission with a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The...Merck & Co Inc • July 31st, 2008 • Pharmaceutical preparations • Delaware
THIS FIRST AMENDMENT TO THE CHOLESTEROL GOVERNANCE AGREEMENT is made as of December 18, 2001, by and among MSP Distribution Services (C) LLC, MSP Marketing Services (C) LLC, MSP Technology (US) Company LLC, Merck Cardiovascular Health Company, Merck Technology (US) Company, Inc., Schering MSP Corporation, Schering Sales Management, Inc., Schering Sales Corporation, Schering MSP Pharmaceuticals L.P., MSP Singapore Company, LLC (the “Singapore Partnership”), MSD Technology Singapore Pte. Ltd., MSD Ventures Singapore Pte. Ltd., Schering-Plough (Singapore) Pte. Ltd., Schering-Plough (Singapore) Research Pte. Ltd., Schering Corporation, Schering-Plough Corporation, a New Jersey corporation (“S-P”), and Merck & Co., Inc., a New Jersey corporation (“M”).
ContractMaster Merial Venture Agreement • July 31st, 2008 • Merck & Co Inc • Pharmaceutical preparations • Delaware
Confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission with a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The location of an omitted portion is indicated by an asterisk within brackets (“[*]”).
